What Happened?
La Jolla, CA-based Shoreline-Biosciences Appointed Kleanthis Xanthopoulos as Chairman and Chief Executive Officer
About the Company
Shoreline Biosciences is a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage (iMACs) platforms. The company`s cellular design technologies are built on a deep understanding of iPSC differentiation, immune cell biology and genetic engineering that enable the development of specific effector cell types, including iNK cells and iMACs as allogeneic "off-the-shelf" cellular immunotherapies designed for durability, scalability, safety, and efficacy. Shoreline is advancing a pipeline of programs towards the clinic, on its own and with its strategic partners, Kite, a Gilead Company, and BeiGene, a global pharmaceutical company. Shoreline Biosciences is headquartered in San Diego, CA.
About the Person
Kleanthis Xanthopoulos is Chairman and Chief Executive Officer at Shoreline Biosciences. Previously, Kleanthis held various senior HR leadership roles in the industry.
Info Source
News
Short Profile